메뉴 건너뛰기




Volumn 32, Issue 4, 2009, Pages 369-374

Treatment of metastatic breast cancer: A large observational study on adherence to french prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab

Author keywords

Adequation of the trastuzumab prescription to the guidelines; Costs; Metastatic breast cancer; Trastuzumab

Indexed keywords

AMETANTRONE; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOTEMUSTINE; GEMCITABINE; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

EID: 69349083132     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31818c08d3     Document Type: Article
Times cited : (16)

References (16)
  • 1
    • 37049183697 scopus 로고
    • Human Breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG. Human Breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987;235:177-182.
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3
  • 5
    • 32244435101 scopus 로고    scopus 로고
    • Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: Results of a randomized phase II trial by the M77001 study group
    • Marty M, Cognetti F, Maraninchi D, et al. Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: results of a randomized phase II trial by the M77001 study group. J Clin Oncol. 2005;23:4247-4250.
    • (2005) J Clin Oncol , vol.23 , pp. 4247-4250
    • Marty, M.1    Cognetti, F.2    Maraninchi, D.3
  • 7
    • 69349095288 scopus 로고    scopus 로고
    • Adjuvant Trastuzumab treatment
    • French National Cancer Institute - French agency for sanitary security of health products.
    • French National Cancer Institute - French agency for sanitary security of health products. Adjuvant Trastuzumab treatment. Protocole temporaire de traitement en situation adjuvante. 2005.
    • (2005) Protocole Temporaire de Traitement en Situation Adjuvante
  • 8
    • 0346218233 scopus 로고    scopus 로고
    • Chemotherapy costs
    • Levy C, Bonastre J. Chemotherapy costs. Bull Cancer. 2003;9:976-982.
    • (2003) Bull Cancer , vol.9 , pp. 976-982
    • Levy, C.1    Bonastre, J.2
  • 10
    • 55449105261 scopus 로고    scopus 로고
    • Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: A cost-effectiveness analysis
    • Poncet B, Bachelot T, Colin C, et al. Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am J Clin Oncol. 2008;4:363-368.
    • (2008) Am J Clin Oncol , vol.4 , pp. 363-368
    • Poncet, B.1    Bachelot, T.2    Colin, C.3
  • 11
    • 0041885349 scopus 로고    scopus 로고
    • Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
    • Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003;21:2889-2895.
    • (2003) J Clin Oncol , vol.21 , pp. 2889-2895
    • Burstein, H.J.1    Harris, L.N.2    Marcom, P.K.3
  • 13
    • 34548178720 scopus 로고    scopus 로고
    • Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
    • DOI 10.1002/cncr.22885
    • Burstein HJ, Keshavia A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007;110:965-972. (Pubitemid 47312860)
    • (2007) Cancer , vol.110 , Issue.5 , pp. 965-972
    • Burstein, H.J.1    Keshaviah, A.2    Baron, A.D.3    Hart, R.D.4    Lambert-Falls, R.5    Marcom, P.K.6    Gelman, R.7    Winer, E.P.8
  • 16
    • 33846568336 scopus 로고    scopus 로고
    • American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    • Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18.
    • (2007) Arch Pathol Lab Med , vol.131 , pp. 18
    • Wolff, A.C.1    Hammond, M.E.2    Schwartz, J.N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.